Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/News/Unlocking Hope: ACE Inhibitors Show Powerful Potential in Reducing Mortality for Idiopathic Pulmonary Fibrosis Patients
News

Unlocking Hope: ACE Inhibitors Show Powerful Potential in Reducing Mortality for Idiopathic Pulmonary Fibrosis Patients

By adminitfy
January 27, 2026 2 Min Read

A recent study published in the Chest Journal reveals that angiotensin-converting enzyme (ACE) inhibitors may play a significant role in decreasing all-cause mortality among patients with idiopathic pulmonary fibrosis (IPF). This revelation has sparked interest in repurposing ACE inhibitors, a class of medications traditionally used to treat conditions like hypertension and congestive heart failure-ailments that frequently co-exist with IPF, which often affects individuals over 50 years old, particularly men. The median survival rate for patients diagnosed with IPF typically ranges from three to five years, making effective treatment strategies critical.

Research conducted with patient-level electronic health records from the Clinical Practice Research Data (CPRD) GP Online Database included individuals diagnosed with IPF between January 2002 and January 2019, aged between 40 and 85 years. The analysis aimed to compare mortality rates in IPF patients treated with ACE inhibitors against those suffering from chronic obstructive pulmonary disease (COPD), another chronic respiratory condition with overlapping comorbidities. The study involved a sample of 3,579 IPF patients matched 1:1 with an equal number of COPD patients for robust comparison.

Of the IPF cohort, 1,328 were treated with ACE inhibitors. Among them, 1,117 deaths were documented (86%) compared to 1,900 deaths (84%) in those not using the medication. In a Cox regression analysis, ACE inhibitors showed a significant association with improved survival rates (HR, 0.99; 95% CI, 0.92-1.06; P = .72). More importantly, a multivariable Cox regression analysis adjusted for confounding factors indicated an independent association between ACE inhibitor use and reduced mortality (HR, 0.82; 95% CI, 0.75-0.91; P < .0001).

Interestingly, the causes of death among ACE inhibitor users predominantly included respiratory complications (45%) and cardiovascular issues (18%). In contrast, the non-user group saw higher rates of respiratory-related deaths (48%) but lower cardiovascular fatalities (11%). However, when adjusted for all potential causes of death, ACE inhibitors did not significantly correlate with a reduction in respiratory-related mortality.

When the ACE inhibitor group in the IPF cohort was compared to the COPD group, where 717 deaths (20%) occurred in users versus 1,692 (47%) in non-users, no significant influence on mortality was established (HR, 1.09; 95% CI, 0.96-1.23; P = .180).

The retrospective nature of the study presents limitations regarding causal inference, and potential confounding factors might remain, despite using propensity score matching. Additionally, IPF diagnoses were derived from electronic health records, raising concerns of possible coding inaccuracies. Nonetheless, the authors note that the resultant survival rates suggest the impact of these discrepancies is minimal.

As the researchers concluded, “These findings highlight the value of investigating well-established medications for new therapeutic roles in progressive diseases such as IPF, where current treatment options remain limited.” They advocate for prospective trials to confirm these findings and further delve into the therapeutic potential of ACE inhibitors for patients battling IPF.

This study opens new avenues for treatment in IPF, emphasizing the need for continued exploration of existing medications to address the pressing challenges faced by patients.

Tags: ACE inhibitors, idiopathic pulmonary fibrosis, COPD, all-cause mortality, clinical research, respiratory diseases

Original Source: https://www.ajmc.com/view/ace-inhibitors-linked-to-reduced-mortality-in-patients-with-idiopathic-pulmonary-fibrosis
Category :
Tags:
Publish Date: 2026-01-27 03:30:00

Author

adminitfy

Follow Me
Other Articles
Senator Ted Cruz Voices Strong Opposition to India Trade Deal with Vance, Navarro, and Trump
Previous

Senator Ted Cruz Voices Strong Opposition to India Trade Deal with Vance, Navarro, and Trump

Trump's Bold Move: US Tariffs on South Korea Soar to 25% Amid Trade Dispute
Next

Trump’s Bold Move: US Tariffs on South Korea Soar to 25% Amid Trade Dispute

No Comment! Be the first one.

Leave a Reply Cancel reply

You must be logged in to post a comment.

Search...

Recent Posts

  • Meghalaya Project Backs 8,000 Artistes; Shillong Eyes Music Capital
    Meghalaya Project Backs 8,000 Artistes; Shillong Eyes Music Capital
    by adminitfy
    November 20, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • Meghalaya Project Backs 8,000 Artistes; Shillong Eyes Music Capital
  • Kuki Civil Society Bodies Seek Missing Man’s Safe Return in Ukhrul
  • Assam: Barpeta, Bajali Polio Drive to Cover 2.9 Lakh Children
  • From $12B to $3.68B: The New Logic of SaaS Consolidation
  • AI Courses in 2027: The Shocking Truth About Learning
  • November 2026 (630)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.